Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases

Hematol Oncol. 2018 Dec;36(5):801-803. doi: 10.1002/hon.2545. Epub 2018 Sep 6.

Authors

Andrea Visentin^{1

2}, Elena Campello³, Edoardo Scomazzon¹, Luca Spiezia³, Silvia Imbergamo¹, Stefano Pravato¹, Francesco Piazza^{1

2}, Gianpietro Semenzato^{1

2}, Paolo Simioni³, Livio Trentin^{1

2}

Affiliations

¹ Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
² Venetian Institute of Molecular Medicine, Centro di Eccellenza per la Ricerca Biomedica Avanzata, Padua, Italy.
³ Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padua, Padua, Italy.

PMID: 30110712
DOI: 10.1002/hon.2545

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Aged
Aged, 80 and over
Atrial Fibrillation / drug therapy*
Dabigatran / administration & dosage*
Female
Humans
Lymphoproliferative Disorders / drug therapy*
Piperidines
Pyrazoles / administration & dosage*
Pyrimidines / administration & dosage*

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Dabigatran
Adenine

Grants and funding